Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $59.6 million.

  • ARS Pharmaceuticals' Cash & Equivalents rose 5018.03% to $59.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.6 million, marking a year-over-year increase of 5018.03%. This contributed to the annual value of $50.8 million for FY2024, which is 2839.75% down from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Cash & Equivalents stood at $59.6 million, which was up 5018.03% from $51.5 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Cash & Equivalents ranged from a high of $374.2 million in Q1 2021 and a low of $36.6 million during Q2 2024
  • Its 5-year average for Cash & Equivalents is $138.6 million, with a median of $71.0 million in 2023.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Cash & Equivalents soared by 25049.53% in 2022, and later plummeted by 7021.41% in 2023.
  • Over the past 5 years, ARS Pharmaceuticals' Cash & Equivalents (Quarter) stood at $60.1 million in 2021, then surged by 250.5% to $210.5 million in 2022, then tumbled by 66.29% to $71.0 million in 2023, then dropped by 28.4% to $50.8 million in 2024, then grew by 17.2% to $59.6 million in 2025.
  • Its last three reported values are $59.6 million in Q3 2025, $51.5 million for Q2 2025, and $39.9 million during Q1 2025.